Skip to main content
Equibles
PVLA logo

PVLA · Palvella Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track PVLA — free

Use PVLA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PVLA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$123.92 +0.96 (+0.78%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.77B
Shares
14.41M
Volume · Oct 20 263.35K Avg daily vol (3M) 212.9K

Palvella Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Palvella Therapeutics, Inc. (PVLA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-15
Palvella Therapeutics, Inc. (PVLA) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Palvella Therapeutics, Inc. (PVLA) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript
Confident tone Cutorin rapamycin and pipeline expansion NDA progress and FDA approval timeline Regulatory designations (breakthrough/fast-track/orphan)
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Palvella Therapeutics, Inc. (PVLA) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Palvella Therapeutics, Inc. (PVLA) Q1 2026 Earnings Call Transcript
Confident tone Phase 3 SELVA results and NDA progress Pipeline expansion beyond lead indication U.S. commercial launch readiness
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Palvella Therapeutics, Inc. (PVLA) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-11
Palvella Therapeutics, Inc. (PVLA) Q3 2025 Earnings Call
Diluted EPS
$-1.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Palvella Therapeutics, Inc. (PVLA) Q2 2025 Earnings Call
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Palvella Therapeutics, Inc. (PVLA) Q1 2025 Earnings Call
Diluted EPS
$-0.74
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Palvella Therapeutics, Inc. (PVLA) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q4
2023-03-29
Palvella Therapeutics, Inc. (PVLA) Q4 2022 Earnings Call
Revenue
$5.85M*
▼ 30.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Palvella Therapeutics, Inc. (PVLA) Q3 2022 Earnings Call
Revenue
$5.37M
▲ 32.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2022 Earnings Call
Revenue
$3.70M
▲ 12.6% YoY
Diluted EPS
$-11.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Palvella Therapeutics, Inc. (PVLA) Q1 2022 Earnings Call
Revenue
$10.99M
▼ 29.7% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q3
2021-11-02
Palvella Therapeutics, Inc. (PVLA) Q3 2021 Earnings Call
Revenue
$4.06M
▲ 38% YoY
Diluted EPS
$-19.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Palvella Therapeutics, Inc. (PVLA) Q2 2021 Earnings Call
Revenue
$3.29M
▼ 70.8% YoY
Diluted EPS
$-20.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Palvella Therapeutics, Inc. (PVLA) Q1 2021 Earnings Call
Revenue
$15.63M
▲ 17.9% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
Palvella Therapeutics, Inc. (PVLA) Q4 2020 Earnings Call
Revenue
$1.88M*
▼ 89.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Palvella Therapeutics, Inc. (PVLA) Q3 2020 Earnings Call
Revenue
$2.94M
▼ 80.6% YoY
Diluted EPS
$-20.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Palvella Therapeutics, Inc. (PVLA) Q2 2020 Earnings Call
Revenue
$11.25M
▲ 110.9% YoY
Diluted EPS
$-7.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Palvella Therapeutics, Inc. (PVLA) Q1 2020 Earnings Call
Revenue
$13.26M
▲ 55.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Palvella Therapeutics, Inc. (PVLA) Q4 2019 Earnings Call
Revenue
$17.27M*
▲ 251.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–22 of 22 webcasts
Key facts CIK 1583648 CUSIP 697947109 13F (30d) 13 filings 13 filers Visit website Investor relations